SE9302203D0 - Composition for ophthalmic use - Google Patents

Composition for ophthalmic use

Info

Publication number
SE9302203D0
SE9302203D0 SE19939302203A SE9302203A SE9302203D0 SE 9302203 D0 SE9302203 D0 SE 9302203D0 SE 19939302203 A SE19939302203 A SE 19939302203A SE 9302203 A SE9302203 A SE 9302203A SE 9302203 D0 SE9302203 D0 SE 9302203D0
Authority
SE
Sweden
Prior art keywords
composition
ophthalmic use
enhancing
eye
viscosity
Prior art date
Application number
SE19939302203A
Other languages
English (en)
Other versions
SE9302203L (sv
SE501482C2 (sv
Inventor
*Urtti Arto
*Jaervinen Tomi
*Suhonen Pekka
*Lehmussaari Kari
*Reunamaeki Timo
*Alaranta Sakari
*Oksala Olli
*Pohjala Esko
*Hanhijaervi Hannu
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Priority to SE9302203A priority Critical patent/SE501482C2/sv
Publication of SE9302203D0 publication Critical patent/SE9302203D0/sv
Priority to PCT/FI1994/000270 priority patent/WO1995000144A1/en
Priority to AU69731/94A priority patent/AU6973194A/en
Priority to LTIP1970A priority patent/LT3525B/lt
Priority to EE9400040A priority patent/EE9400040A/xx
Publication of SE9302203L publication Critical patent/SE9302203L/sv
Publication of SE501482C2 publication Critical patent/SE501482C2/sv

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9302203A 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning SE501482C2 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9302203A SE501482C2 (sv) 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
PCT/FI1994/000270 WO1995000144A1 (en) 1993-06-24 1994-06-17 Composition for ophthalmic use
AU69731/94A AU6973194A (en) 1993-06-24 1994-06-17 Composition for ophthalmic use
LTIP1970A LT3525B (en) 1993-06-24 1994-06-23 Composition for ophthalmic use
EE9400040A EE9400040A (et) 1993-06-24 1994-08-18 Oftalmiliseks otstarbeks mõeldud kompositsioon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302203A SE501482C2 (sv) 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning

Publications (3)

Publication Number Publication Date
SE9302203D0 true SE9302203D0 (sv) 1993-06-24
SE9302203L SE9302203L (sv) 1994-12-25
SE501482C2 SE501482C2 (sv) 1995-02-27

Family

ID=20390417

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9302203A SE501482C2 (sv) 1993-06-24 1993-06-24 Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning

Country Status (5)

Country Link
AU (1) AU6973194A (sv)
EE (1) EE9400040A (sv)
LT (1) LT3525B (sv)
SE (1) SE501482C2 (sv)
WO (1) WO1995000144A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
WO2023225113A1 (en) * 2022-05-18 2023-11-23 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
TW200402B (sv) * 1990-08-13 1993-02-21 Senju Pharma Co
FI98815C (sv) * 1990-11-30 1997-08-25 Santen Oy Förfarande för framställning av nya farmakologiskt användbara esterderivat av bispilokarpinsyra

Also Published As

Publication number Publication date
LTIP1970A (en) 1995-01-31
SE9302203L (sv) 1994-12-25
SE501482C2 (sv) 1995-02-27
AU6973194A (en) 1995-01-17
WO1995000144A1 (en) 1995-01-05
LT3525B (en) 1995-11-27
EE9400040A (et) 1995-12-15

Similar Documents

Publication Publication Date Title
ATE210943T1 (de) Ophthalmologisches abgabesystem
ATE300936T1 (de) Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
ATE51522T1 (de) Formulierung nicht irritierender ophthalmischer waesseriger zusammensetzungen fuer okulartherapeutische mittel.
MX9306708A (es) Composiciones de espuma de lucha contra el fuego, de un solvente polar de baja viscosidad.
MY105761A (en) Dispensing devices powered by hydrogel
DK0495421T3 (da) Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
BR0007147A (pt) Composição de tensìdio contendo tensìdio gemini e co-anfifila, sua preparação e aplicação
MXPA03011947A (es) Formulaciones de olopatidina para administracion topica.
DK0781547T3 (da) Ophthalmisk formulering baseret på natriumhyaluronat til anvendelse i øjen-kirugi
NO971192L (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
MX9203653A (es) Composiciones amfotericas y formas polimericas de los alfa-hidroxiacidos.
DK0418339T3 (da) Præparat og fremgangsmåde til forebyggelse af sammenvoksninger mellem kropsvæv
WO2002045662A3 (en) Anhydrous creams, lotions and gels
MXPA05008909A (es) Formulacion intranasal de rotigotina.
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
BR0210013A (pt) Gel oftálmico de pirenzepina
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
EP1354602A4 (en) MEDICAL COMPOSITIONS WITH DIURETIC AGENT AND IMPROVING INSULIN RESISTANCE
DE69412760T2 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
SE9302203D0 (sv) Composition for ophthalmic use
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
AU2001285944A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof